![(11bS)-2,6-二-9-蒽-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-2,6-Di-9-anthracenyl-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)](https://img.nicebiochem.com/20250502/89f20c8981610e19156414693f4e35e9bbcfb53340c3e8864505e2df67fc248b.png)
(11bS)-2,6-二-9-蒽-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-2,6-Di-9-anthracenyl-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二-1-芘基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-di-1-pyrenyl-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0446 | 50mg
-
(11bR)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二-1-芘基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bR)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-di-1-pyrenyl-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0444 | 50mg
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二-1-萘基-4-氧化物二萘并[2,1-d:1',2'-f][1,3,2]二噁磷杂庚英 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-di-1-naphthalenyl-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-1384 | 100mg
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双(三苯基)-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis(triphenylsilyl)-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-0821 | 50mg
-
(11bS)-2,6-二(4-氯苯基)-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f]的[1,3,2]二氧磷杂七环 (11bS)-2,6-Bis(4-chlorophenyl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0386 | 50mg
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双(4-硝基苯基)-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis(4-nitrophenyl)-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0416 | 50mg
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二甲基-2-萘基-4-氧化物二萘并[2,1-d:1',2'-f][1,3,2]二噁磷杂庚英 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-di-2-naphthalenyl-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-1379 | 100mg
中文名称：(11bS)-2,6-二-9-蒽-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环
英文名称：(11bS)-2,6-Di-9-anthracenyl-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
分子式：C48H37O4P；分子量：708.8。
您正在浏览的产品：(11bS)-2,6-二-9-蒽-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环
手机版：(11bS)-2,6-二-9-蒽-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环
本公司销售的所有产品仅供实验科研使用，不用于人体及临床诊断。
2. 色谱条件：C18反相色谱柱，流动相为乙腈-0.1%甲酸水梯度洗脱；
3. 质谱参数：电喷雾离子源（ESI-），碰撞能量优化至目标物特征碎片离子强度最大。
以上信息仅供参考，请以相应标准的原文为准！